索拉非尼联合TACE术治疗中晚期肝细胞癌的临床疗效分析  

Clinical Efficacy of Sorafenib Combined with TACE for Patients with Advanced Liver Carcinoma

作　　者：刘岗[1] 钟武装[1] 赵玮[1] 王伟中[1] 乐德[1] 

机构地区：[1]广州军区广州总医院,510010

出　　处：《实用癌症杂志》2016年第12期1970-1973,共4页The Practical Journal of Cancer

摘　　要：目的探讨索拉非尼联合TACE术治疗中晚期肝细胞癌的临床疗效。方法根据治疗方法不同将97例中晚期肝细胞癌患者分为实验组(47例)和对照组(50例),对照组患者给予单纯TACE术治疗,实验组患者在此基础上加用索拉非尼治疗,比较两组患者近期疗效和远期疗效。结果实验组患者疗程结束后总有效率明显高于对照组,差异具有显著性(P<0.05);实验组患者治疗后血清VEGF水平明显低于对照组,差异具有显著性(P<0.05);实验组患者手足反应、腹泻、皮疹/脱皮以及高血压发生率及严重程度均明显高于对照组,差异具有显著性(P<0.05);两组患者乏力、消化道反应、脱发、骨髓抑制和肝功能异常发生率及严重程度比较,差异无统计学意义(P>0.05);实验组患者2年生存率及中位生存期明显优于对照组,差异具有显著性(P<0.05)。结论索拉非尼能够有效提高TACE术的近期疗效和远期生存率,但会明显增加患者手足反应、腹泻、皮疹/脱皮以及高血压等不良反应发生率,可作为中晚期肝细胞癌治疗的优选方案,但需注意预防不良反应。Objective To explore the clinical efficacy of sorafenib combined with TACE for patients with advanced liver carcinoma. Methods 97 cases of patients with advanced liver carcinoma were divided into the experiment group（47 cases） and the control group（50 cases）. The control group were treated by TACE,the experiment group were treated by sorafenib combined with TACE. The Short-term and long-term effects of the 2 groups were compared. Results The total effective rate after treatment in the experiment group were higher than the control group （ P 〈 0.05 ） ; The levels of VEGF in the experiment group were lower than the control group（ P 〈 0.05 ） ; Hand-foot reaction, diarrhea, rash/peeling, hypertensive in the experiment group were higher than the control group （P 〈 0.05 ） ;There had no significant difference in the rate of feeble, gastrointestinal reaction, alopecia, my- elosuppression, hepatic dysfunction between the 2 groups （ P 〉 0.05 ） ; 2-year survival rate and mean survival in the experiment group were higher than the control group （ P 〈 0.05 ）. Conclusion Sorafenib combined with TACE can increase short-term and long-term effects for patients with advanced liver carcinoma, but it increase the hand-foot reaction, diarrhea, rash/peeling, hypertensive. It can be used as optimization treatment for middle-late hepatocellular carcinoma,it need to pay attention to adverse reactions.

关 键 词：索拉非尼 TACE 中晚期肝细胞癌 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]